Skip to main content

Advertisement

Table 1 Demographic details and baseline characteristics of study participants

From: Systemic Immuno-metabolic alterations in chronic obstructive pulmonary disease (COPD)

  HNS (n = 16) HS (n = 13) TS-COPD (n = 14) p-value
Age (y) 53.38 ± 10.43 60.15 ± 8.754 68.36 ± 8.924 < 0.001
Gender (M/F) 8 M/8F 13 M/0F 14 M/0F N/A
BMI 24.31 ± 3.909 23.71 ± 2.814 19.75 ± 3.12 < 0.01
Fasting BSL (mg/dL) 88.63 ± 12.1 91.54 ± 16.22 95.31 ± 11.68 NS
Smoking history, Pack years (Ex:Current) N/A 32.69 ± 17.37 (2:11) 39.45 ± 29.98 (6:8) NS
FEV1 (% Predicted) 104.3 ± 10.57 97.72 ± 9.394 51.09 ± 26.24 < 0.001
FVC (% Predicted) 102.3 ± 13.3 95.08 ± 11.46 85.85 ± 20.78 < 0.05
FVC/FEV1% 102.5 ± 6.387 103.3 ± 4.426 58.12 ± 19.49 < 0.001
COPD gold stage (I/II/III/IV) N/A N/A 3/2/6/3 N/A
Monocytes (%) 5.786 ± 0.699 7.5 ± 1.446 7.556 ± 1.667 < 0.01
(/μL) 435.9 ± 119 595.6 ± 148.9 619.4 ± 224 < 0.05
Neutrophils (%) 55.93 ± 12.39 53.58 ± 8.051 60.44 ± 6.966 NS
(/μL) 4186 ± 1170 4390 ± 1431 5033 ± 1656 NS
Lymphocytes (%) 34.43 ± 10.41 34.83 ± 7.158 29.11 ± 5.667 NS
(/μL) 2612 ± 1124 2810 ± 792.1 2359 ± 705.4 NS
Eosinophils (%) 3.857 ± 2.685 4.083 ± 3.37 2.889 ± 1.833 NS
(/μL) 280.3 ± 194.4 345.8 ± 371.1 266.2 ± 260.8 NS
  1. Data is represented as mean ± standard deviation. HNS Healthy non-smokers, HS Healthy smokers and TS-COPD Tobacco-smoking – COPD subjects. ANOVA statistical analysis was performed and p < 0.05 was considered significant. NS Non-significant and N/A Not applicable